HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Efficacy of trilostane for the treatment of equine Cushing's syndrome.

AbstractREASONS FOR PERFORMING STUDY:
Trilostane, a competitive 3-beta hydroxysteroid dehydrogenase inhibitor, has been used successfully to control clinical signs and cortisol excess in canine pituitary dependent hyperadrenocorticism.
OBJECTIVES:
Trilostane was evaluated for its efficacy in resolving clinical and clinicopathological abnormalities of equine Cushing's syndrome (ECS) and to assess its safety.
METHODS:
Twenty horses (mean age 21 years) diagnosed with ECS were followed for 1 or 2 years. Affected horses received 0.4-1 mg/kg (mean 0.5 mg/kg) trilostane once daily.
RESULTS:
Clinical signs assessed over 1 or 2 years, showed a reduction in lethargy in all horses post treatment. Polyuria and/or polydipsia, present in 11 horses, was reduced in all after treatment. Recurrent or chronic laminitis, present in 16 horses, improved in 13/16 (81%) of cases. There were no side effects reported. Combined dexamethasone suppression and thyrotropin releasing hormone (TRH) stimulation tests were significantly different before and 30 days following therapy. There was a significant reduction (P = 0.01) of cortisol following TRH administration before (160 +/- 53.0 nmol/l) and after (130 +/- 46.1 nmol/l) trilostane.
CONCLUSIONS:
Trilostane caused improvement in clinical signs in horses, without side effects, and a corresponding decrease in cortisol response to TRH administration.
POTENTIAL RELEVANCE:
Trilostane may be a useful therapy for the treatment of ECS. Further work comparing the effects of trilostane and pergolide is warranted.
AuthorsC M McGowan, R Neiger
JournalEquine veterinary journal (Equine Vet J) Vol. 35 Issue 4 Pg. 414-8 (Jun 2003) ISSN: 0425-1644 [Print] England
PMID12880011 (Publication Type: Journal Article)
Chemical References
  • Enzyme Inhibitors
  • Dihydrotestosterone
  • Adrenocorticotropic Hormone
  • 3-Hydroxysteroid Dehydrogenases
  • trilostane
  • Hydrocortisone
Topics
  • 3-Hydroxysteroid Dehydrogenases (antagonists & inhibitors)
  • Adrenocorticotropic Hormone (blood)
  • Animals
  • Cushing Syndrome (drug therapy, veterinary)
  • Dihydrotestosterone (analogs & derivatives, therapeutic use)
  • Enzyme Inhibitors (therapeutic use)
  • Female
  • Horse Diseases (drug therapy)
  • Horses
  • Hydrocortisone (blood)
  • Male
  • Safety
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: